Forest acquisition whets M&A appetite

Share this article:

Actavis's Forest acquisition has piqued industry interest in Teva Pharmaceutical. Bloomberg reports that the Maxim Group thinks that the Actavis move has boosted “prospects that Teva could be acquired next.” Among Maxim's reasons: a new CEO, a shrinking executive board, and a cost-cutting strategy.

Teva would not comment on Bloomberg's story.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M inVISION